From Yahoo Finance: 2025-04-16 11:17:00

MannKind Corp. (NASDAQ:MNKD) is being scrutinized among biotech penny stocks. Concerns arise post-Peter Marks’s FDA exit. Stifel’s Paul Matteis advises investors to seek biotech companies less FDA-dependent due to recent regulatory unpredictability. Investors now favor companies with de-risked profiles and commercial launches over those reliant on FDA consistency.

MNKD ranks 10th among top biotech penny stocks. MNKD focuses on therapeutic products for endocrine and orphan lung diseases. Afrezza inhalation powder generated $18 million in Q4 2024, up 18% YoY. Potential approval for pediatric market in early 2026 could boost sales to over $200 million annually, driving MNKD’s growth potential.

MNKD’s growth is promising, but AI stocks offer even greater potential. Cheapest AI stock may deliver high returns in a shorter timeframe. Consider exploring other AI opportunities. For more stock insights, check out the “20 Best AI Stocks To Buy Now” and “30 Best Stocks to Buy Now According to Billionaires” lists.

Read more: Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds?